{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:29:30Z","timestamp":1793734170371,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling. CD19 functions as the dominant signaling component of a multimolecular complex on the surface of mature B cells, alongside complement receptor CD21, and the tetraspanin membrane protein CD81 (TAPA-1), as well as CD225. Through study of CD19 transgenic and knockout mouse models, it becomes clear that CD19 plays a critical role in maintaining the balance between humoral, antigen-induced response and tolerance induction. This review also summarized latest clinical development of CD19 antibodies, anti-B4-bR (an immunotoxin conjugate), blinatumomab (BiTE), and SAR3419 (huB4-DM4), a novel antibody-drug conjugate.<\/jats:p>","DOI":"10.1186\/2162-3619-1-36","type":"journal-article","created":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T22:15:06Z","timestamp":1354140906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":531,"title":["CD19: a biomarker for B cell development, lymphoma diagnosis and therapy"],"prefix":"10.1186","volume":"1","author":[{"given":"Kemeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,29]]},"reference":[{"key":"34_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1756-8722-5-64","volume":"5","author":"S Cang","year":"2012","unstructured":"Cang S, Mukhi N, Wang K, Liu D: Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012, 5: 64. 10.1186\/1756-8722-5-64","journal-title":"J Hematol Oncol"},{"issue":"1","key":"34_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1475-2867-12-38","volume":"12","author":"J Zhao","year":"2012","unstructured":"Zhao J, Xu Z, Liu D, Lu Q: Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell Int 2012,12(1):38. 10.1186\/1475-2867-12-38","journal-title":"Cancer Cell Int"},{"issue":"1","key":"34_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1756-8722-5-70","volume":"5","author":"M Firer","year":"2012","unstructured":"Firer M, Gellerman G: Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol 2012,5(1):70. 10.1186\/1756-8722-5-70","journal-title":"J Hematol Oncol"},{"key":"34_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000075685","volume":"7","author":"RH Carter","year":"2004","unstructured":"Carter RH, Barrington RA: Signaling by the CD19\/CD21 complex on B cells. Curr Dir Autoimmun 2004, 7: 4\u201332.","journal-title":"Curr Dir Autoimmun"},{"issue":"Suppl 1:S12","key":"34_CR5","first-page":"11","volume":"7","author":"D Thierry-Mieg","year":"2006","unstructured":"Thierry-Mieg D, Thierry-Mieg J: AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol 2006,7(Suppl 1:S12):11\u201314.","journal-title":"Genome Biol"},{"issue":"2","key":"34_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/BF00189519","volume":"35","author":"LJ Zhou","year":"1992","unstructured":"Zhou LJ, Ord DC, Omori SA, Tedder TF: Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes. Immunogenetics 1992,35(2):102\u2013111.","journal-title":"Immunogenetics"},{"key":"34_CR7","doi-asserted-by":"publisher","first-page":"D130","DOI":"10.1093\/nar\/gkr1079","volume":"40","author":"KD Pruitt","year":"2012","unstructured":"Pruitt KD, Tatusova T, Brown GR, Maglott DR: NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy. Nucleic Acids Res 2012, 40: D130-D135. Database issue 10.1093\/nar\/gkr1079","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"34_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/0167-5699(94)90273-9","volume":"15","author":"JH Kehrl","year":"1994","unstructured":"Kehrl JH, Riva A, Wilson GL, Thevenin C: Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 1994,15(9):432\u2013436. 10.1016\/0167-5699(94)90273-9","journal-title":"Immunol Today"},{"issue":"10","key":"34_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","volume":"5","author":"TF Tedder","year":"2009","unstructured":"Tedder TF: CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009,5(10):572\u2013577. 10.1038\/nrrheum.2009.184","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"34_CR10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4049\/jimmunol.143.2.712","volume":"143","author":"TF Tedder","year":"1989","unstructured":"Tedder TF, Isaacs CM: Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes, A new member of the immunoglobulin superfamily. J Immunol 1989,143(2):712\u2013717.","journal-title":"J Immunol"},{"key":"34_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/0-387-24180-9_16","volume":"560","author":"KM Haas","year":"2005","unstructured":"Haas KM, Tedder TF: Role of the CD19 and CD21\/35 receptor complex in innate immunity, host defense and autoimmunity. Adv Exp Med Biol 2005, 560: 125\u2013139. 10.1007\/0-387-24180-9_16","journal-title":"Adv Exp Med Biol"},{"issue":"1\u20133","key":"34_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1385\/IR:26:1-3:045","volume":"26","author":"RH Carter","year":"2002","unstructured":"Carter RH, Wang Y, Brooks S: Role of CD19 signal transduction in B cell biology. Immunol Res 2002,26(1\u20133):45\u201354.","journal-title":"Immunol Res"},{"issue":"2","key":"34_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1385\/IR:31:2:119","volume":"31","author":"CJ Del Nagro","year":"2005","unstructured":"Del Nagro CJ, Otero DC, Anzelon AN, Omori SA, Kolla RV, Rickert RC: CD19 function in central and peripheral B-cell development. Immunol Res 2005,31(2):119\u2013131. 10.1385\/IR:31:2:119","journal-title":"Immunol Res"},{"issue":"1","key":"34_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0923-1811(99)00043-2","volume":"22","author":"S Sato","year":"1999","unstructured":"Sato S: CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity. J Dermatol Sci 1999,22(1):1\u201310. 10.1016\/S0923-1811(99)00043-2","journal-title":"J Dermatol Sci"},{"issue":"9","key":"34_CR15","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.4049\/jimmunol.149.9.2841","volume":"149","author":"LE Bradbury","year":"1992","unstructured":"Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF: The CD19\/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol 1992,149(9):2841\u20132850.","journal-title":"J Immunol"},{"issue":"4","key":"34_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1006\/smim.1998.9999","volume":"10","author":"M Fujimoto","year":"1998","unstructured":"Fujimoto M, Poe JC, Inaoki M, Tedder TF: CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol 1998,10(4):267\u2013277. 10.1006\/smim.1998.9999","journal-title":"Semin Immunol"},{"issue":"5","key":"34_CR17","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.4049\/jimmunol.1201000","volume":"189","author":"JC Poe","year":"2012","unstructured":"Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF: A c-Myc and Surface cd19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol 2012,189(5):2318\u20132325. 10.4049\/jimmunol.1201000","journal-title":"J Immunol"},{"issue":"18","key":"34_CR18","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1056\/NEJMoa051568","volume":"354","author":"MC van Zelm","year":"2006","unstructured":"van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patino PJ, van Dongen JJ, et al.: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006,354(18):1901\u20131912. 10.1056\/NEJMoa051568","journal-title":"N Engl J Med"},{"key":"34_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/0-387-46530-8_12","volume":"596","author":"DM Mills","year":"2007","unstructured":"Mills DM, Stolpa JC, Cambier JC: Modulation of MHC class II signal transduction by CD19. Adv Exp Med Biol 2007, 596: 139\u2013148. 10.1007\/0-387-46530-8_12","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"34_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","volume":"6","author":"TF Tedder","year":"1997","unstructured":"Tedder TF, Inaoki M, Sato S: The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997,6(2):107\u2013118. 10.1016\/S1074-7613(00)80418-5","journal-title":"Immunity"},{"issue":"4","key":"34_CR21","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/eji.200939848","volume":"40","author":"N Ishiura","year":"2010","unstructured":"Ishiura N, Nakashima H, Watanabe R, Kuwano Y, Adachi T, Takahashi Y, Tsubata T, Okochi H, Tamaki K, Tedder TF, et al.: Differential phosphorylation of functional tyrosines in CD19 modulates B-lymphocyte activation. Eur J Immunol 2010,40(4):1192\u20131204. 10.1002\/eji.200939848","journal-title":"Eur J Immunol"},{"issue":"1","key":"34_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1074-7613(00)00007-8","volume":"13","author":"M Fujimoto","year":"2000","unstructured":"Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, Tedder TF: CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000,13(1):47\u201357. 10.1016\/S1074-7613(00)00007-8","journal-title":"Immunity"},{"issue":"6","key":"34_CR23","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1172\/JCI45851","volume":"122","author":"EY Chung","year":"2012","unstructured":"Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A: CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest 2012,122(6):2257\u20132266. 10.1172\/JCI45851","journal-title":"J Clin Invest"},{"issue":"12","key":"34_CR24","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1182\/blood-2006-12-061812","volume":"109","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, Vaisitti T, Billington R, Bergui L, Omede P, Genazzani AA, Malavasi F: CD38\/CD19: a lipid raft-dependent signaling complex in human B cells. Blood 2007,109(12):5390\u20135398. 10.1182\/blood-2006-12-061812","journal-title":"Blood"},{"issue":"1","key":"34_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-2567.2012.03602.x","volume":"137","author":"F Vences-Catalan","year":"2012","unstructured":"Vences-Catalan F, Rajapaksa R, Levy S, Santos-Argumedo L: The CD19\/CD81 complex physically interacts with CD38 but is not required to induce proliferation in mouse B lymphocytes. Immunology 2012,137(1):48\u201355. 10.1111\/j.1365-2567.2012.03602.x","journal-title":"Immunology"},{"issue":"1","key":"34_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.4049\/jimmunol.172.1.370","volume":"172","author":"A Cherukuri","year":"2004","unstructured":"Cherukuri A, Shoham T, Sohn HW, Levy S, Brooks S, Carter R, Pierce SK: The tetraspanin CD81 is necessary for partitioning of coligated CD19\/CD21-B cell antigen receptor complexes into signaling-active lipid rafts. J Immunol 2004,172(1):370\u2013380.","journal-title":"J Immunol"},{"issue":"6538","key":"34_CR27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/376352a0","volume":"376","author":"RC Rickert","year":"1995","unstructured":"Rickert RC, Rajewsky K, Roes J: Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995,376(6538):352\u2013355. 10.1038\/376352a0","journal-title":"Nature"},{"issue":"1","key":"34_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/1074-7613(95)90157-4","volume":"3","author":"P Engel","year":"1995","unstructured":"Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF: Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995,3(1):39\u201350. 10.1016\/1074-7613(95)90157-4","journal-title":"Immunity"},{"issue":"5053","key":"34_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1126\/science.1373518","volume":"256","author":"RH Carter","year":"1992","unstructured":"Carter RH, Fearon DT: CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992,256(5053):105\u2013107. 10.1126\/science.1373518","journal-title":"Science"},{"issue":"1","key":"34_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bcmd.2004.03.003","volume":"33","author":"LJ Cooper","year":"2004","unstructured":"Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC: Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 2004,33(1):83\u201389. 10.1016\/j.bcmd.2004.03.003","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"34_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/cyto.b.20030","volume":"63","author":"W Yang","year":"2005","unstructured":"Yang W, Agrawal N, Patel J, Edinger A, Osei E, Thut D, Powers J, Meyerson H: Diminished expression of CD19 in B-cell lymphomas. Cytometry B Clin Cytom 2005,63(1):28\u201335.","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"34_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/jcp.51.5.364","volume":"51","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D: Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998,51(5):364\u2013369. 10.1136\/jcp.51.5.364","journal-title":"J Clin Pathol"},{"issue":"3","key":"34_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/10428190290012146","volume":"43","author":"H Ishikawa","year":"2002","unstructured":"Ishikawa H, Tsuyama N, Mahmoud MS, Fujii R, Abroun S, Liu S, Li FJ, Kawano MM: CD19 expression and growth inhibition of tumours in human multiple myeloma. Leuk Lymphoma 2002,43(3):613\u2013616. 10.1080\/10428190290012146","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"34_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0145-2126(93)90026-H","volume":"17","author":"H Tsuchiya","year":"1993","unstructured":"Tsuchiya H, ElSonbaty SS, Nagano K, Watanabe M, Migita M, Mitsubuchi H, Kaneko Y, Matsuda I: Acute myeloblastic leukemia (ANLL-M2) with t(8;21)(q22;q22) variant expressing lymphoid but not myeloid surface antigens with a high number of G-CSF receptors. Leuk Res 1993,17(4):375\u2013377. 10.1016\/0145-2126(93)90026-H","journal-title":"Leuk Res"},{"issue":"2","key":"34_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0145-2126(94)90131-7","volume":"18","author":"SH Khalil","year":"1994","unstructured":"Khalil SH, Jackson JM, Qari MH, Pyle H: Acute myeloblastic leukemia (AML-M2) expressing CD19 B-cell lymphoid antigen without myeloid surface antigens. Leuk Res 1994,18(2):145. 10.1016\/0145-2126(94)90131-7","journal-title":"Leuk Res"},{"issue":"6","key":"34_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/BF01741331","volume":"32","author":"A Hekman","year":"1991","unstructured":"Hekman A, Honselaar A, Vuist WM, Sein JJ, Rodenhuis S, ten Bokkel Huinink WW, Somers R, Rumke P, Melief CJ: Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer immunology, immunotherapy: CII 1991,32(6):364\u2013372. 10.1007\/BF01741331","journal-title":"Cancer immunology, immunotherapy: CII"},{"issue":"1","key":"34_CR37","first-page":"37","volume":"40","author":"LT Vlasveld","year":"1995","unstructured":"Vlasveld LT, Hekman A, Vyth-Dreese FA, Melief CJ, Sein JJ, Voordouw AC, Dellemijn TA, Rankin EM: Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer immunology, immunotherapy: CII 1995,40(1):37\u201347.","journal-title":"Cancer immunology, immunotherapy: CII"},{"issue":"9","key":"34_CR38","first-page":"2392","volume":"5","author":"ML Grossbard","year":"1999","unstructured":"Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM: A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clinical cancer research: an official journal of the American Association for Cancer Research 1999,5(9):2392\u20132398.","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"21","key":"34_CR39","first-page":"252","volume":"118","author":"MS Topp","year":"2011","unstructured":"Topp MS, Goekbuget N, Zugmaier G, Viardot A, Stelljes M, Neumann S, Horst HA, Reichle A, Marks RE, Brueggemann M, et al.: Anti-CD19 BiTE Blinatumomab induces high complete remission rate in adult patients with relapsed b-precursor all: updated results of an ongoing Phase II Trial. ASH Annual Meeting Abstracts 2011,118(21):252.","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"12","key":"34_CR40","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-08-2808","volume":"15","author":"AM Al-Katib","year":"2009","unstructured":"Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C: Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2009,15(12):4038\u20134045. 10.1158\/1078-0432.CCR-08-2808","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"20","key":"34_CR41","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","volume":"17","author":"V Blanc","year":"2011","unstructured":"Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM: SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies. Clin Cancer Res 2011,17(20):6448\u20136458. 10.1158\/1078-0432.CCR-11-0485","journal-title":"Clin Cancer Res"},{"issue":"22","key":"34_CR42","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, et al.: Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012,30(22):2776\u20132782. 10.1200\/JCO.2011.39.4403","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"95","key":"34_CR43","doi-asserted-by":"publisher","first-page":"95ra","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011,3(95):95ra-73.","journal-title":"Sci Transl Med"},{"issue":"8","key":"34_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011,365(8):725\u2013733. 10.1056\/NEJMoa1103849","journal-title":"N Engl J Med"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2162-3619-1-36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T01:27:37Z","timestamp":1687829257000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/2162-3619-1-36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1186\/2162-3619-1-36","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]},"assertion":[{"value":"31 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"36"}}